Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zuo, Qiang ^a   Liu, Jing ^a   Zhang, Jingwen ^a   Wu, Mengwan ^a   Guo, Lihong ^a   Liao, Wangjun ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; 3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; ANTINEOPLASTIC AGENT; CHROMONE DERIVATIVE; ENZYME INHIBITOR; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB; TYRPHOSTIN;

ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STOMACH TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MORPHOLINES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TRASTUZUMAB; TYRPHOSTINS;

EID: 84932642558     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep11634     Document Type: Article

References (29)

1. Tai, W., Mahato, R., Cheng, K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 146, 264-275 (2010).
2. Miller, T. W., Rexer, B. N., Garrett, J. T., & Arteaga, C. L. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 13, 224 (2011).
3. Kim, J. W. et al. The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen. Anticancer Res. 32, 1547-1553 (2012).
4. Hudis, C. A. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med. 357, 39-51 (2007).
5. Tinoco, G. et al. Treating breast cancer in the 21st century: emerging biological therapies. J Cance. 4, 117-132 (2013).
6. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344, 783-792 (2001).
7. Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376, 687-697 (2010).
8. Wehrman, T. S. et al. A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions. Proc Natl Acad Sci USA. 103, 19063-19068 (2006).
9. Fujita, T. et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer. 94, 247-252 (2006).
10. Chan, C. T., Metz, M. Z., Kane, S. E. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res Treat. 91, 187-201 (2005).
11. Lu, Y. et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst. 93, 1852-1857 (2001).
12. Bayrak, M. et al. Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer. Clin Transl Oncol. 15, 307-312 (2013).
13. Urasaki, Y. et al. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res. 61, 1964-1969 (2001).
14. Jang, H. D. et al. PTEN regulation by the Akt/GSK-3beta axis during RANKL signaling. Bone. 55, 126-131 (2013).
15. Zhang, H. B. et al. Baicalein induces apoptosis in esophageal squamous cell carcinoma cells through modulation of the PI3K/Akt pathway. Oncol Lett. 5, 722-728 (2013).
16. Zhang, B. G. et al. microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN. Oncol Rep. 27, 1019-1026 (2012).
17. Li, Y. et al. High-expression of DJ-1 and loss of PTEN associated with tumor metastasis and correlated with poor prognosis of gastric carcinoma. Int J Med Sci. 10, 1689-1697 (2013).
18. Berns, K. et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 12, 395-402 (2007).
19. Park, B. H., Davidson, N. E. PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance? Cancer Cell. 12, 297-299 (2007).
20. Lima, E. M. et al. Molecular study of the tumour suppressor gene PTEN in gastric adenocarcinoma in Brazil. Clin Exp Med. 5, 129-132 (2005).
21. Wang, J. Y. et al. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas. Virchows Arch. 442, 437-443 (2003).
22. Huang, Q., Nai, Y. J., Jiang, Z. W., Li, J. S. Change of the growth hormone-insulin-like growth factor-I axis in patients with gastrointestinal cancer: related to tumour type and nutritional status. Br J Nutr. 93, 853-858 (2005).
23. Gallardo, A. et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer. 106, 1367-1373 (2012).
24. Nahta, R. et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65, 11118-11128 (2005).
25. Ding, Y. et al. Receptor tyrosine kinase ErbB2 translocates into mitochondria and regulates cellular metabolism. Nat Commun. 3, 1271 (2012).
26. Diermeier, S. et al. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res. 304, 604-619 (2005).
27. Xia, W. et al. Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res. 66, 1640-1647 (2006).
28. Nahta, R. et al. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 64, 3981-3986 (2004).
29. Kute, T. et al. Development of Herceptin resistance in breast cancer cells. Cytometry A. 57, 86-93 (2004).